Selection of Genetic Variants and Multilocus Risk Score Generation
We originally selected 51 SNPs previously identified to be associated with CHD. 5 Of the 51 SNPs, 14 were directly genotyped ( Table II in the Data Supplement). For the 37 imputed SNPs, the imputation r 2 was >95% in 30 SNPs, between 90% and 85% in 3 SNPs, and between 70% and 85% in 4 SNPs (rs11556924, rs17514846, rs2895811, and rs4773144). These 4 SNPs with imputation r 2 <0.85 were not included in the estimation of the GRSs. Best-guessed imputed genotypes were considered in the generation of the GRSs.
Four multilocus GRSs were computed as the sum of the number of risk alleles across all genetic variants after weighting each one by its estimated effect size in the CARDIoGRAMplusC4D (Coronary Artery Disease Genome Wide Replication And Meta-Analysis Plus the Coronary Artery Disease [C4D] Genetics) Consortium. 5 We defined 3 GRSs (GRS_8, GRS_12, and GRS_36) that included genetic variants associated with CAD but not with risk factors included in the classical risk functions (total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, blood pressure, smoking, and diabetes mellitus) in accordance to the data available at GWAS catalog reviewed in August 2010 for GRS_8 and GRS_12 and in January 2013 for GRS_36. We also defined a GRS_51 that included the 47 variants reported to be associated with CAD dependently and independently of their association with risk factors included in the classical risk functions. For clarification purposes, GRS_12 contains 8 variants from GWAS, GRS_36 contains 32 variants from GWAS, and GRS_51 contains 47 variants from GWAS, and all of them contain 4 variants to incorporate the ALOX5AP haplotype. These GWAS usually analyze individual genetic variants and do not take into consideration haplotypes. The ALOX5AP presents an haplotype, called haplotype B, that has been reported to be associated with CHD in different populations. [12] [13] [14] [15] [16] [17] This haplotype consisted of rs10507391-A, rs93155050-A, rs17222842-G, and rs17216473-A (these 4 SNPs were imputed). Because the haplotype diversity could capture genetic variability associated risk better than individual genetic variants, and there were consistent data supporting the association between the ALOX5AP Haplotype B and CHD, we included this haplotype variant in 3 of the 4 GRSs (GRS_12, GRS_36, and GRS_51). No significant deviations from Hardy-Weinberg equilibrium were noted for any of the SNPs. We have verified in 1000 genomes SNAP (SNP Annotation and Proxy Search; https:// www.broadinstitute.org/mpg/snap/ldsearch.php) that all 51 SNPs are independent (linkage disequilibrium r 2 <0.50). Weighted GRSs were calculated using the formula where β i is the estimated effect size reported for each variant, SNP i is the number of copies of each individual SNP evaluated (with values 0, 1, or 2), and n is number of SNPs. A weight of 0.131 was applied to the presence of the haplotype. 15, 18 Ten-year CHD risk was estimated using the Framingham risk function described by Wilson et al. 19 We did not use the more recently developed Pooled Cohorts Equation 1 because it applies to all cardiovascular disease, including stroke, whereas the CARDIoGRAMplusC4D Consortium focused on coronary artery disease. Age, sex, education level, race/ethnicity, smoking status, alcohol consumption, body mass index, and family history of heart disease were available from the RPGEH survey; systolic and diastolic blood pressures were obtained from primary care outpatient visits closest to the survey date, and lipid panels and serum creatinine (closest to survey date) were obtained from the health plan laboratory database. Diabetes mellitus status was derived by cross-linkage with the Kaiser Permanente of Northern California diabetes mellitus registry. Hypertension and hypercholesterolemia treatment was ascertained using the Pharmacy Information Management System (PIMS), relying on prescription dispensing (at the time of the RPGEH survey or ≤2 years prior) of drugs falling into the corresponding therapeutic class. Estimation of glomerular filtration rate was done using the Modification of Diet in Renal Disease Study (MDRD) formula. 4
Statistical Analyses
We used standard parametric and nonparametric methods to compare the characteristics of different groups of individuals according to quintiles of the GRSs. We then tested the association of each GRS (both as a continuous variable in SD units and as quintiles with the lowest quintile as the referent group) with incident CHD using Cox proportional hazards models, with sequential adjustment for classical CHD risk factors. Subjects were right-censored at different times depending on incident events, vital status, or health plan membership status. Model a included only the GRS (ie, no covariates); model b included the individual FRS variables (age, sex, total cholesterol, highdensity lipoprotein cholesterol, systolic and diastolic blood pressure, smoking status, and diabetes mellitus); model c included model b covariates plus family history of heart disease, and model d included additional covariates that are not part of the FRS, namely education level, body mass index, antihypertensives, lipid-lowering drugs, and alcohol consumption. We expected 5% of the cohort to develop CHD, in which case we had 80% power to detect a hazard ratio of 1.04 per standard deviation of the GRS in the full sample. To test the proportionality of hazards assumption, we plotted Schoenfeld residuals against time and tested the interaction of each GRS with follow-up time. There was no visual evidence of departure from zero slope, and none of the interactions were statistically significant (P=0.10 for GRS_8, P=0.08 for GRS_12, P=0.87 for GRS_36, and P=0.52 for GRS_51). Therefore, there was no evidence that the proportionality of hazards assumption was violated.
In addition, we used 3 different statistical approaches to assess the potential value of including the GRSs in risk prediction: (1) the goodness-of-fit of the models using the Hosmer-Lemeshow test (with 10 bins to define risk strata) 5 ; (2) the discriminative capacity of the model using the concordance index (Harrell's C statistic) 6 ; and (3) reclassification improvement using the NRI index and the integrated discrimination improvement index. 20 For the assessment of reclassification improvement, we adopted the same 4 risk categories used in the prior study of GRS_8 (low, intermediate-low, intermediate-high, and high, with cutoff points 0%-9.9%, 10%-14.9%, 15%-19.9%, and ≥20%, respectively). 6 We calculated the expected number of events at 10 years in each risk category using Kaplan-Meier estimates. A bootstrapping method was used to construct confidence intervals for integrated discrimination improvement and NRI to account for uncertainty in the Kaplan-Meier estimates, as suggested by Steyerberg and Pencina. 21 To correct for bias in the NRI estimation among individuals with intermediate risk, we used the method proposed by Paynter and Cook. 22 To theoretically assess the effect of the GRSs in improving clinical utility and outcomes, we applied the concept of 2-stage risk screening. 23 We assumed that statin medication is allocated to the subjects at the high-risk category (≥20%) and that statins would reduce the risk of major coronary events by 24%. 24 
Results
The mean (SD) age of the cohort was 59 (9) years, and 67% of the subjects were female ( Table 1) . Eighty-two percent of the patients were college educated; 5% reported current smoking; and 38% were former smokers. Although 57% of the patients reported low or medium alcohol intake, 4% reported high alcohol intake. The prevalence of diabetes mellitus was 12%, and 23% of the patients had a body mass index in the obesity range. Forty-six percent of the patients were on antihypertensive medication, and about a third was taking cholesterol-lowering agents. Moderately to severe kidney dysfunction (glomerular filtration rate <60) was present in 16% of the individuals. Overall, 72% of the patients had a low (<10%) FRS, 16% had an intermediate-low (10%-15%) FRS, 7% had an intermediate-high (16%-20%) FRS, and 6% had a high (>20%) FRS. Thirty-one percent of the patients reported family history of angina/heart attack.
The Pearson correlation coefficients between the 4 GRSs ranged from 0.64 (between GRS_8 and GRS_51) to 0.94 (between GRS_8 and GRS_12). GRSs means were significantly higher in subjects with events compared with subjects without events (all P<0.0001; Figure 1 ).
As expected by design (ie, selection of SNP components), GRS_8, GRS_12, and GRS_36 were not associated with the classical risk factors, with the exception of slightly higher use of cholesterol-lowering drugs by subjects in quintile 5 versus quintile 1 (Table IIIA- A greater prevalence of family history of angina/heart attack in quintile 5 versus quintile 1 was found in all GRSs. On the contrary, and also consistent with expectation, GRS_51 was significantly associated with high-density lipoprotein cholesterol, total cholesterol, and the FRS in addition to use of cholesterol-lowering drugs and family history of angina/ heart attack. After a mean (SD) follow-up time of 5.9 (1.5) years, 1864 incident CHD events were documented (1077 in men and 787 in women). For all the GRSs, there was a positive linear association among the quintiles of GRS and age-adjusted rates of incident CHD, and the trend lines for the 4 GRSs were overlapping ( Figure 2 ). In unadjusted models, each SD increment in GRS was associated with 1.21, 1.20, 1.23, and 1.23 increased hazard of incident CHD for GRS_8, GRS_12, GRS_36, and GRS_51, respectively ( Table 2) . Adjustment for FRS individual components and additional available covariates had no appreciable effect on the risk estimates. No evidence of gender interaction was found in either minimally or fully adjusted models (all P>0.60); thus, no results are presented separately for men and women. When the GRSs were modeled as quintiles, quintile 5 (versus quintile 1) was associated with hazard ratios (95% confidence interval [CI]) of 1.75 (95% CI, 1.51-2.03), 1.74 (95% CI, 1.50-2.02), 1.77 (95% CI, 1.53-2.05), and 1.95 (95% CI, 1.68-2.27) for GRS_8, GRS_12, GRS_36, and GRS_51, respectively, in the unadjusted models. Again, there was little or no attenuation of the risk estimates after multivariable adjustment. The strength of independent association of all the individual risk factors with incident CHD is shown in Table IV in the Data Supplement.
The results of all the Hosmer-Lemeshow tests showed a good fit of the models, including the GRS in the equation (all P values ≥0.20; Table 3 ). The area under the curve after the addition of the GRSs to models already containing the FRS changed only marginally, although the results were statistically significant for all GRSs. For all the GRSs, both the integrated discrimination improvement and the NRI presented a better performance when analyzing only the subset of individuals classified in the intermediate-risk category. Notably, the contribution to reclassification was mainly from subjects who went on to develop CHD. Both reclassification as a continuous value (integrated discrimination improvement) and as a categorical value (NRI) was better for GRS_8 and GRS_12 than for GRS_36 and GRS_51. The reclassification tables are provided in Table V in using GRS_8 or GRS_12 and 7% of subjects using GRS_36 or GRS_51 to high-risk category ( Table 4 ). We estimated that systematic treatment with statins to all the subjects in the intermediate group would have prevented 168 CHD events (699×0.24), avoiding 1 CHD event for every 70 individuals treated (11 770/168) based on the theoretical efficacy of statins (24% reduction in CHD incidence). 20 The number of subjects reclassified to the high-risk group required to be treated to prevent 1 CHD with statins were 36 for GRS_8 and GRS_12, 41 for GRS_36, and 43 for GRS_51 (Table  4 ). Thus, the inclusion of GRS_8 or GRS_12 in a 2-stage screening scenario would be ≈1.9x more effective in preventing events than the systematic use of statins in the intermediate-risk group (the corresponding figures for GRS_36 and GRS_51 were 1.7 and 1.6, respectively).
Discussion
In our cohort, 4 GRSs, including 8 to 51 genetic variants previously shown to predict CHD, were independently associated with CHD incidence. The 4 GRSs improved the discrimination capacity of the Framingham risk function and reclassification, particularly in the intermediate-risk group. Of note, the extent of reclassification was slightly better using GRS_8 and GRS_12 compared with that using GRS_36 and GRS_51 and was mostly driven by incident CHD cases. We have also assessed the GRS clinical utility and its effect on clinical outcomes. Using the GRSs in a 2-stage screening scenario, 7% to 9% of the intermediate-risk individuals are reclassified into a high-risk group. We estimated that this approach would prevent 1.6× to 1.9× more events than would systematic use of statins in the intermediate-risk group.
We replicate here the association between GRS_8 and risk of CHD previously reported in the REGICOR (Registre Gironi del COR) and Framingham cohorts. 6 Further, we tested the comparative utility of 3 additional GRSs enriched with additional SNPs previously known to be associated with CHD. For any of the 4 GRSs, and after multivariable adjustment, there was more than a 1.75-fold increase in the age-adjusted rate of incident of CHD comparing quintile 5 to quintile 1. The strength of the unadjusted association was similar across enrichment, with increasing number of SNPs included in the GRS. As expected (because some of the SNPs selected for GRS_51 were related to risk factors), we observed some attenuation of the risk relation in models including GRS_51. Therefore, there was no clear advantage of GRS_12, GRS_36, or GRS_51 over GRS_8. It remains to be seen if incorporation of a much higher number of SNPs associated with CHD using a more liberal threshold for tested SNPs in GWAS could improve the GRSs analyzed here. These results are in agreement with previous studies that have analyzed the association between different GRSs and CHD incidence. [25] [26] [27] [28] [29] [30] Interestingly and similar to prior studies, [31] [32] [33] this association was independent of other cardiovascular risk factors and of family history of CHD, indicating the value of genomic information above and beyond self-reported family history. 32 From the clinical standpoint, the GRSs have to demonstrate their value at different levels in accordance to guidelines. 34 The first level is the assessment of the predictive added value: do the GRSs add predictive information to established, standard risk markers? After the addition of the GRSs to models already containing the FRS, we observed a small but statistically significant increment in the discrimination capability (C statistic). The improvement in the discrimination capacity has been reported in some studies 5,6,25,32,35 but not in others. 26, 29, 31, 33, 36, 37 Second, does the GRS changed predicted risk sufficiently to change clinical attitude/recommended therapy as determined by where the subject is allocated? 2 New statistical metrics, such as reclassification, have been developed to characterize that change. 38 In our study, we report a modest (4%-5% for all GRSs) but significant reclassification when including the GRSs in the predictive risk function. The extent of reclassification was more evident (between 7% and 9%) when considering only the intermediate-risk group, which is the most interesting group from the clinical point of view. Our results in this group are, therefore, in the low range of prior reports, 6, 23, 25, 31 where NRI ranged from 6% to 27%. However, it should be noted that these previous estimates were not corrected for bias as described by Paynter and Cook. 22 Third, does use of the GRSs improve clinical outcomes, especially when tested in a randomized clinical trial? This level is much more difficult to evaluate mainly because of the high cost of clinical trials and the availability of potentially useful markers. Alternatively, we have performed a Model 1a indicates GRS/SD as a continuous variable only. Model 1b, GRS/SD as a continuous variable plus individual Framingham risk score variables (age, sex, total cholesterol, HDL-C, systolic blood pressure, diastolic blood pressure, diabetes mellitus, smoking status). Model 1c: Model 1b covariates plus family history of heart disease. Model 1d: Model 1c covariates plus education level, body mass index, anti-hypertensives, lipid lowering, alcohol consumption. Model 2a: GRS as quintiles only. Model 2b: GRS as quintiles plus individual Framingham risk score variables (age, sex, total cholesterol, HDL-C, systolic blood pressure, diastolic blood pressure, diabetes mellitus, smoking status). Model 2c: Model 2b covariates plus family history of heart disease. Model 2d: Model 2c covariates plus education level, body mass index, antihypertensives, lipid lowering, alcohol consumption. CHD indicates coronary heart disease; CI, confidence interval; GERA, Genetic Epidemiology Resource in Adult Health and Aging; GRS, genetic risk scores; and HDL-C, high-density lipoprotein cholesterol. theoretical analysis using a 2-stage risk screening model and selecting the group at intermediate CHD risk as published before. 23, 39 Our results indicate that use of genetic testing in identifying the subjects at high risk could prevent between 1.6× and 1.9× more events than systematic allocation of statins to all individuals of the intermediate group.
These results are more conservative to those reported by Tikkanen et al, 23 who reported that the genetic testing would prevent 2.5× more events than would random allocation of statins. Additionally, we have analyzed whether the up-reclassified subjects would have a higher benefit from statins, similarly to the work by Mega et al. 39 They noted that, in primary prevention, their GRS would identify subjects who could benefit more from statin therapy and that the mean individuals needed to treat with statin to prevent 1 CHD in a 10-year period would move from 61 to 33. Our results are similar to those reported by Mega et al because 36 to 43 individuals would need to be treated to avoid 1 CHD event in the genetically screened population. We think that these results are conservative because we have only used the statin effect associated with the decrease in 1 mmol/L of total cholesterol when for patients at high risk a higher decrement is recommended. 2, 40 Moderate-intensity statin therapy is expected to lower low-density lipoprotein Hosmer-Lemeshow chi-square* Model with FRS 23.9 (9); 0.005 23.9 (9); 0.005 23.9 (9); 0.005 23.9 (9); 0.005
Model with FRS+GRS 9.9 (9); 0.36 10.9 (9); 0. cholesterol by ≈30% to <50% and high-intensity statin therapy by ≈≥50%. 40 Moreover, we have not taken into consideration that there may be an increment in the compliance of patients after receiving genetic testing. 41 Statins are considered effective in reducing cardiovascular morbidity and mortality in high-risk patients. However, although adherence to statins improves morbidity and mortality, it remains suboptimal. For some researchers, one of the most important causes of nonadherence is the so-called statin intolerance, mainly because of muscle-related symptoms.
In any case, nonadherence is a general problem to any drug and is not necessarily associated to adverse reactions. In the case of statins, the knowledge that patients with high genetic risk obtain a great benefit from statin therapy may motivate patient to adhere to statin therapy. A higher adherence to statins and a higher reduction of cardiovascular risk has already been observed in patients by the knowledge of a relevant genetic contribution to their disease. [42] [43] [44] Fourth, does use of the GRS improved clinical outcomes sufficiently to justify the additional cost of testing and treatment? GRS_8 has already proved to be cost-effective in a theoretical model based on data from 2 cohorts. 45 Future work needs to be done to establish the cost-effectiveness of GRS_12, GRS_36, and GRS_51. We have identified some limitations in our study. Because of population admixture and the fact that the genetic variants were ascertained in a European population, 5 these results may not be generalizable to non-European populations. Future work by our group and others will address the need for ethnic-specific validation of these 4 multilocus GRS, as well as development of ethnic-specific multilocus GRSs. Moreover, the mean follow-up of the study was 5.9 years when common risk functions estimate 10-year risk. Although routine lipid panels in clinical care require 8 hours of fasting, we did not have information on compliance with the fasting requirement or actual hours of fasting. The GERA cohort has a high representation of the upper end of the educational spectrum, which could limit its generalizability to populations with lower educational attainment. On the contrary, the study has several strengths, including an unprecedented large sample size and availability of high-quality genotypic data and of traditional cardiovascular risk factors and other variables (such as body mass index, alcohol intake, renal function, and family history of CAD) not included in the Framingham equation. Rather than a Health Maintenance Organization (claims data), Kaiser Permanente of Northern California is an integrated healthcare system where utilization comes from their own hospitals and outpatient clinics. As long as members remain in the plan, ascertainment of inpatient services is essentially complete. Among people in the GERA cohort, >97% have at least 5 years of continuous membership and >83% have at least 10 years of continuous membership; their average duration of membership is 23.5 years. We have focused on incident rather than on prevalent events. We have also used state-of-the-art methodology to assess the performance of novel biomarkers. 22, 34 Finally, the Kaiser population has a higher proportion of individuals with ideal cardiovascular metrics in comparison to those published for adults in United States, 46 which places more individuals at the low-risk category and makes it more difficult for GRSs to reclassify subjects to high-risk categories. Despite this, we have observed similar results for GRS_8 than previously reported. 6 This study goes beyond a simple replication of prior results and fills gaps in knowledge, such as the relative contribution of GRSs with increasing number of loci and different known relatedness to risk factors and the link to clinical utility. In addition, we think that this work is a significant and important contribution to the field of cardiovascular genetics for the following reasons: (1) this is large, well-characterized cohort with individual data and not a meta-analysis; (2) it demonstrates the potential of data generated by an integrated healthcare system to conduct robust, cost-effective, large-scale genetic epidemiological studies; (3) our analysis is noteworthy because it indicates the usefulness of genetic information in a population with good control for risk factors, which places more individuals at the low-risk category and makes it more difficult for GRSs to reclassify subjects to high-risk categories.
In summary, the analyzed GRSs improved the predictive capacity of a classical risk function, especially in the intermediate-risk group. The clinical utility results presented here build the evidence and the case for incorporation of parsimonious multilocus GRSs in predictive algorithms for primary prevention of CHD and may help advance the realization of precision medicine.
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